Pioglitazone and rosiglitazone are peroxisome proliferator activated receptor gamma (PPAR-γ,) agonists (thiazolidinediones) that also have anti-inflammatory activities in COVID-19 patients and have been suggested for treatment [154,155]. This evidence concerns the gene PPARG and COVID-19.